A ligand-activated transcription factor (TF) and type II nuclear receptor (NR), farnesoid X receptor (FXR), has been identified as a clinical target for therapeutic intervention for NASH and other chronic liver diseases. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.